<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620355</url>
  </required_header>
  <id_info>
    <org_study_id>BG2109-301</org_study_id>
    <nct_id>NCT05620355</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.</brief_title>
  <official_title>A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of BG2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio Genuine (Shanghai) Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio Genuine (Shanghai) Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the superior efficacy versus placebo of&#xD;
      BG2109 alone and in combination with add-back therapy for the reduction of heavy menstrual&#xD;
      bleeding associated with uterine fibroids in premenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, parallel group, double-blind, placebo-controlled&#xD;
      phase 3 study investigating the efficacy and safety of BG2109 alone and in combination with&#xD;
      add-back therapy (Estradiol 1 mg / Norethindrone Acetate 0.5 mg) for the treatment of uterine&#xD;
      fibroids in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2022</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24.</measure>
    <time_frame>The last 28 days before the Week 24.</time_frame>
    <description>MBL will be determined using the Alkaline Hematin method (AHM). Responder means whose MBL less than 80mL during the last 28 days before the Week 24 and more than 50% reduction in MBL compared to the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reduced MBL before the Week 24.</measure>
    <time_frame>From baseline to Week 24.</time_frame>
    <description>Reduced MBL means MBL less than 80ml and more than 50% reduction in MBL compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of amenorrhea at the Week 24.</measure>
    <time_frame>From baseline to Week 24.</time_frame>
    <description>Amenorrhea is defined as having 0 data (or volume below the lower limit of quantification) from the AHM of MBL from the central laboratory or missing of AHM data with reported of &quot;spotting&quot; or &quot;no bleeding&quot; in the eDiary for 35 days before Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to amenorrhea before the Week 24.</measure>
    <time_frame>From baseline to Week 24.</time_frame>
    <description>The number of days from Study Day 1 to the first day having amenorrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of menstrual bleeding in the last 28 days before the Week 24.</measure>
    <time_frame>The last 28 days before the Week 24.</time_frame>
    <description>Record the number of days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels at the Week 24 in the subgroup of subjects with anemia.</measure>
    <time_frame>The Week 24.</time_frame>
    <description>Anemia is defined as hemoglobin below 12g/dL at baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Responders at the Week 52.</measure>
    <time_frame>The last 28 days before the Week 52.</time_frame>
    <description>Responder is defined as above.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to reduced MBL before the Week 52.</measure>
    <time_frame>From baseline to Week 52.</time_frame>
    <description>Reduced MBL is defined as above.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of amenorrhea at the Week 52.</measure>
    <time_frame>From baseline to Week 52.</time_frame>
    <description>Amenorrhea is defined as above.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to amenorrhea before the Week 52.</measure>
    <time_frame>From baseline to Week 52.</time_frame>
    <description>The number of days from Study Day 1 to the first day having amenorrhea.</description>
  </other_outcome>
  <other_outcome>
    <measure>By 52 weeks, the number of days with menstrual bleeding per 28 days.</measure>
    <time_frame>From baseline to Week 52.</time_frame>
    <description>Record the number every 28days.</description>
  </other_outcome>
  <other_outcome>
    <measure>Score of Uterine Fibroids related pain, symptoms and quality of life.</measure>
    <time_frame>From Week 12 to Week 64</time_frame>
    <description>Use specified scales.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>The Week 24 and Week 52.</time_frame>
    <description>Assessed by dual-energy X-ray absorptiometry (DXA) scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to Week 64.</time_frame>
    <description>Clinical manifestation，frequency and severity of Treatment-Emergent Adverse Events.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Uterine Fibroids</condition>
  <condition>Heavy Menstrual Bleeding</condition>
  <arm_group>
    <arm_group_label>BG2109 100mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of BG2109 100mg + one tablet of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BG2109 200mg+ABT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of BG2109 100mg + one tablet of add-back therapy, oral, once-daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BG2109</intervention_name>
    <description>BG2109 100mg film coated tablet for oral administration once daily.</description>
    <arm_group_label>BG2109 100mg group</arm_group_label>
    <arm_group_label>BG2109 200mg+ABT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for BG2109</intervention_name>
    <description>Placebo for BG2109 100mg tablet for oral administration once daily.</description>
    <arm_group_label>BG2109 100mg group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for add-back therapy</intervention_name>
    <description>Placebo for add-back therapy tablet for oral administration once daily.</description>
    <arm_group_label>BG2109 100mg group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add-back therapy</intervention_name>
    <description>Estradiol 1 mg / Norethindrone Acetate 0.5 mg for oral administration once daily.</description>
    <arm_group_label>BG2109 200mg+ABT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Subject is an 18 years and older premenopausal woman.&#xD;
&#xD;
          2. Subject's Body Mass Index ≥ 18 kg/m2.&#xD;
&#xD;
          3. Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound.&#xD;
&#xD;
          4. Subject's menstrual cycles is between 21 days and 35 days in the last 3 months.&#xD;
&#xD;
          5. Subject has clinical manifestations of heavy menstrual bleeding.&#xD;
&#xD;
          6. Subject's menstrual blood loss &gt;80mL for at least 2 menstrual periods assessed at&#xD;
             screening using the alkaline hematin method.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. The subject is pregnant or breast-feeding or is planning a pregnancy within the&#xD;
             duration of the treatment period of the study.&#xD;
&#xD;
          2. The subject has a history of uterus surgery that would interfere with the study.&#xD;
&#xD;
          3. The subject's condition is so severe that she will require surgery within 6 months.&#xD;
&#xD;
          4. The subject have had or are currently suffering from any estrogen- dependent&#xD;
             malignancy.&#xD;
&#xD;
          5. The subject has a significant risk of osteoporosis, or have a known history of&#xD;
             osteoporosis or other metabolic bone disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Congjian Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrics &amp; Gynecology Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Chen</last_name>
    <phone>021-58590032</phone>
    <email>Lisa.Chen@Bio-Genuine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site no.28</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.31</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.34</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.11</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.6</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.7</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.17</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.22</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.10</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.3</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.4</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.19</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.21</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.23</name>
      <address>
        <city>Lianyungang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.14</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.15</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.16</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.26</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.18</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.1</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.29</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.8</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.30</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.5</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.2</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.20</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.25</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.13</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site no.32</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>March 19, 2023</last_update_submitted>
  <last_update_submitted_qc>March 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

